24.01.2013 • News

Lanxess Expands Dichlorobenzene Capacity by 15% at Leverkusen Facility

Specialty chemicals company Lanxess has increased its dichlorobenzene capacity by more than 15%. It has done so by installing an additional crystallizer at the Leverkusen site, thereby enabling it to produce more high-purity para-dichlorobenzene for the global market.

Some €3 million has been invested in the capacity expansion for this intermediate for the manufacture of high-performance plastics.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read